COMPARISON OF THE METABOLIC EFFECTS OF CARVEDILOL AND METОPROLOL IN HYPERTENSIVE PATIENTS WITH OVERWEIGHT AND OBESITY. THE CAMELLIA TRIAL
Autor: | S. Y. Martsevich, N. P. Kutishenko, E. V. Shilova, A. D. Deev, S. A. Shalnova, R. G. Oganov, I. A. Veliganina, E. G. Volkova, Yu. E. Voskanjan, L. I. Gapon, P Ya. Dovgalevskij, V. Ya. Ermolina, E. M. Idrisova, N. N. Ilov, A. R. Kiselev, S. Yu. Levashov, V. A. Nevzorova, G. I. Nechaeva, T. N. Panova, I. I. Reznik, V. V. Skibickij, L. A. Sokolova, V. P. Terentev, N. V. Hailo, A. V. Shabalin, T. V. Shnjukova, V. V. Yakusevich |
---|---|
Jazyk: | English<br />Russian |
Rok vydání: | 2016 |
Předmět: | |
Zdroj: | Рациональная фармакотерапия в кардиологии, Vol 5, Iss 2, Pp 33-38 (2016) |
Druh dokumentu: | article |
ISSN: | 1819-6446 2225-3653 |
DOI: | 10.1234/1819-6446-2009-2-33-38 |
Popis: | Aim. To compare two therapies based on carvedilol or metoprolol in hypertensive patients with overweight and obesity.Material and methods. 320 patients with arterial hypertension (1-2 degree) were involved in the study. 160 patients received carvedilol and 160 patients – metoprolol. Both randomized groups were comparable on the main clinical characteristics.Results. By the end of the study both systolic and diastolic blood pressure (SBP, DBP) reduced in both groups рConclusion. The results of open, randomized CAMELLIA trial confirmed antihypertensive effect and good tolerability of carvedilol in common clinical practice as well as demonstrated some its advantages in patients with metabolic syndrome. Carvedilol has positive metabolic effects on lipid, glucose and uric acid levels. Carvedilol therapy is more preferable in patients with arterial hypertension and metabolic risk factors. |
Databáze: | Directory of Open Access Journals |
Externí odkaz: |